Macrophage Migration Inhibitory Factor - A Favorable Marker in Inflammatory Diseases?

Title:Macrophage Migration Inhibitory Factor - A Favorable Marker in Inflammatory Diseases?

Volume: 25 Issue: 5

Author(s): Johannes Hertelendy, Georg Reumuth, David Simons, Christian Stoppe, Bong-Sung Kim, Jan-Philipp Stromps, Paul C. Fuchs, Jurgen Bernhagen, Norbert Pallua and Gerrit Grieb*

Affiliation:

• Department of Plastic Surgery and Hand Surgery, Burn Center, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen,Germany

Keywords: MIF, biomarker, infectious disease, autoimmune disease, cytokine, CD74, CXCR.

Abstract: Background: Macrophage migration inhibitory factor (MIF) was firstly described in the 1960s as a pleiotropic cytokine affecting a variety of immune cells. Different physiological functions mainly involving inflammatory reactions such as chemokine-like function and regulating systemic stress responses have been reported.

Objective: In several clinical studies the use of MIF as a biomarker has been investigated promising support for diseases with an inflammatory aspect such as sepsis, systemic infections and autoimmune diseases. This article in detail reviews clinical data and evaluates the function as biomarker focusing on inflammatory and autoimmune diseases.

Conclusion: Recent studies suggest MIF to be a marker for different inflammatory diseases and might serve as therapeutic target in the future.

Cite this article as:

Hertelendy Johannes , Reumuth Georg , Simons David , Stoppe Christian , Kim Bong-Sung , Stromps Jan-Philipp , Fuchs C. Paul , Bernhagen Jurgen , Pallua Norbert and Grieb Gerrit *, Macrophage Migration Inhibitory Factor - A Favorable Marker in Inflammatory Diseases?, Current Medicinal Chemistry 2018; 25 (5) . https://dx.doi.org/10.2174/0929867324666170714114200